BioSpace

Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study

Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and ...

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due ...
Nasdaq

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

ARO-ALK7 is the first investigational RNAi therapeutic to enter clinical studies that targets a gene expressed in adipose tissue Study initiation highlights Arrowhead’s leadership in the delivery of ...

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLO™ (plozasiran), a small interfering RNA (siRNA) medicine, ...
Los Angeles Business Journal

Arrowhead Hits the Mark

This article has been revised and clarified. Pasadena-based biopharma company Arrowhead Pharmaceuticals Inc. had a double-dose of good news last month. On Nov. 18, Arrowhead announced that it had ...
Nasdaq

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

- In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean ...